The National Tremor Foundation (or NTF as we are known) is an organisation where we aim to provide help, support and advice to all those living with all forms of tremor irrespective of age.
The NTF was first brought to the UK from the USA in 1992 and in 1994 became a registered charity in its own right.
Each year the NTF holds an annual conference, subsidised by the NTF providing members and friends with the opportunity of not only meeting and spending some time together but also asking a panel of experts’ questions that help with improving quality of life.
The NTF produces a newsletter (NTF News) and this is available via post, email and our website. The NTF has developed close links with other UK voluntary organisations including the Parkinson’s Disease Society and the Neurological Alliance and also with international organisations including the European Parkinson’s Disease Association (EPDA) and the International Tremor Foundation.
Misguided beliefs and a lack of awareness mean that many people with this condition never seek medical care though most would benefit from treatment. The NTF dedicates this site to the thousands of people in the UK whose lives are affected by tremor.
1 Dec 2014
The International Essential Tremor Foundationannounced today that it has been honored with a prestigious 2014 Top-Rated Award by GreatNonprofits, the leading provider of user reviews about nonprofit organizations.
25 Nov 2014
Just in time for the holidays, Google is throwing its money, brain power and technology at the humble spoon. Of course these spoons (don't call them spoogles) are a bit more than your basic utensil: Using hundreds of algorithms, they allow people with essential tremors and Parkinson's Disease to eat without spilling.
23 Oct 2014
The aim of this study was to estimate the prevalence and assess the clinical correlates of intention tremor in the legs in essential tremor (ET) patients. Data suggest that intentional leg tremor is common in tremor patients and arm tremor has an intentional component in many ET patients. Intention tremor in the legs, however, has never been systematically evaluated.
International Parkinson and Movement Disorder Society
23 Oct 2014
SAGE Therapeutics (Nasdaq:SAGE) today announced dose initiation of the first patient in a single-center Phase 2a clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with essential tremor. This trial is designed to evaluate the safety, tolerability, pharmacokinetics and activity of SAGE-547 in patients with essential tremor, a neurological disorder that causes involuntary, rhythmic shaking with no known cause. The trial is being conducted under a newly accepted Investigational New Drug filing.